Cyclo Therapeutics Inc (CYTH)
1.37
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
1.37
0.00 (0.00%)
After-Hours: 20:00
Cyclo Therapeutics Enterprise Value: 30.09M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 16, 2024 | 30.09M |
May 15, 2024 | 31.82M |
May 14, 2024 | 31.24M |
May 13, 2024 | 30.96M |
May 10, 2024 | 32.97M |
May 09, 2024 | 32.39M |
May 08, 2024 | 33.83M |
May 07, 2024 | 34.11M |
May 06, 2024 | 34.69M |
May 03, 2024 | 34.11M |
May 02, 2024 | 32.97M |
May 01, 2024 | 32.39M |
April 30, 2024 | 32.68M |
April 29, 2024 | 32.97M |
April 26, 2024 | 26.94M |
April 25, 2024 | 27.80M |
April 24, 2024 | 28.08M |
April 23, 2024 | 25.50M |
April 22, 2024 | 26.94M |
April 19, 2024 | 24.06M |
April 18, 2024 | 25.21M |
April 17, 2024 | 25.50M |
April 16, 2024 | 25.79M |
April 15, 2024 | 26.36M |
April 12, 2024 | 26.94M |
Date | Value |
---|---|
April 11, 2024 | 30.09M |
April 10, 2024 | 30.67M |
April 09, 2024 | 31.53M |
April 08, 2024 | 31.24M |
April 05, 2024 | 28.95M |
April 04, 2024 | 30.09M |
April 03, 2024 | 29.81M |
April 02, 2024 | 32.68M |
April 01, 2024 | 29.81M |
March 28, 2024 | 30.67M |
March 27, 2024 | 30.96M |
March 26, 2024 | 30.96M |
March 25, 2024 | 31.82M |
March 22, 2024 | 33.54M |
March 21, 2024 | 32.68M |
March 20, 2024 | 31.82M |
March 19, 2024 | 35.55M |
March 18, 2024 | 36.70M |
March 15, 2024 | 38.13M |
March 14, 2024 | 35.02M |
March 13, 2024 | 37.01M |
March 12, 2024 | 37.01M |
March 11, 2024 | 37.01M |
March 08, 2024 | 37.87M |
March 07, 2024 | 37.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.768M
Minimum
Nov 22 2022
74.54M
Maximum
May 28 2019
23.31M
Average
21.51M
Median
Jul 14 2023
Enterprise Value Benchmarks
NovaBay Pharmaceuticals Inc | 5.209M |
Palatin Technologies Inc | 23.43M |
iBio Inc | 16.17M |
Theriva Biologics Inc | -8.844M |
Oragenics Inc | 5.770M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -5.642M |
Revenue (Quarterly) | 0.3114M |
Total Expenses (Quarterly) | 5.954M |
EPS Diluted (Quarterly) | -0.23 |
Gross Profit Margin (Quarterly) | 95.02% |
Profit Margin (Quarterly) | -1.81K% |
Earnings Yield | -95.62% |
Normalized Earnings Yield | -95.59 |